BioNTech is a German biotechnology company specializing in the development of personalized immunotherapies for serious diseases, particularly cancer and infectious diseases. Founded in 2008, BioNTech focuses on harnessing the body’s immune system to target and destroy cancer cells. The company gained significant recognition for its role in developing one of the first mRNA-based vaccines for COVID-19, in collaboration with Pfizer. mRNA technology allows for the rapid development of vaccines that instruct cells to produce a protein that triggers an immune response against specific pathogens. BioNTech’s work is not limited to vaccines; it also involves various therapeutic approaches, including cancer therapies, using technologies such as messenger RNA, antibody-drug conjugates, and cell therapy.
BioNTech, based in Mainz, is shifting focus from COVID-19 vaccines to pioneering cancer treatments using mRNA technology. The company outperformed 2024 market expectations with an EPS of €1.08 and revenue…